Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Operating Expenses (2022 - 2026)

Indivior Pharmaceuticals has reported Operating Expenses over the past 5 years, most recently at $139.0 million for Q1 2026.

  • For Q1 2026, Operating Expenses fell 10.9% year-over-year to $139.0 million; the TTM value through Mar 2026 reached $17.0 million, down 98.12%, while the annual FY2025 figure was $34.0 million, 96.3% down from the prior year.
  • Operating Expenses for Q1 2026 was $139.0 million at Indivior Pharmaceuticals, up from -$487.0 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $338.0 million in Q2 2024 and troughed at -$487.0 million in Q4 2025.
  • A 5-year average of -$34.2 million and a median of $8.0 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: skyrocketed 300.0% in 2024 and later crashed 337.56% in 2025.
  • Year by year, Operating Expenses stood at -$460.0 million in 2022, then surged by 59.35% to -$187.0 million in 2023, then surged by 209.63% to $205.0 million in 2024, then plummeted by 337.56% to -$487.0 million in 2025, then soared by 128.54% to $139.0 million in 2026.
  • Business Quant data shows Operating Expenses for INDV at $139.0 million in Q1 2026, -$487.0 million in Q4 2025, and $187.0 million in Q3 2025.